Tags : Post

Novartis Reports Results of Five-year P-III MEASURE 1 and FUTURE

Vartika Singh October 16, 2018

Shots: The P-III MEASURE 1 and FUTURE 1 study involves assessing of Cosentyx (secukinumab) 75/ 150 mg vs PBO @16 wks. or 24 wks. in patients with PsA and AS respectively P-III MEASURE 1 (N=606) and FUTURE 1(N= 371) study results: improvement in ASAS 20 (74% @75mg, 82% @150mg), improvement in signs and symptoms of […]Read More

Amgen Launches Amgevita (adalimumab, biosimilar) in EU to Treat Inflammatory

Vartika Singh October 16, 2018

Shots: Amgevita will be launched in 28 EU countries as well as Norway, Iceland and Liechtenstein making it 3rd EU Amgen’s approved biosimilar EMA approved Amgevita in RA, PsA, AS, nr-axSpA, plague psoriasis, HS, non-infectious panuveitis, CD and UC in adults and CD, plague psoriasis, ERA and JIA in pediatric patients Amgevita is an IgG1 […]Read More

IDEAYA and Pfizer Expand CTC and Supply Agreement for Solid Tumors Harboring GNAQ or GNA11 Mutations

Bausch Health Acquires Option to Purchase Allegro’s Ophthalmology Assets

Inovio Reports FDA’s Partial Clinical Hold on P-II/III Trial of INO-4800 Against COVID-19

Sarepta Reports Two-Year Follow Up Results of SRP-9001 for Duchenne Muscular Dystrophy

Accord Launches Zercepac (biosimilar, trastuzumab) in the UK

Samsung Bioepis to Present P-III Exploratory Analyses Results of Aybintio (bevacizumab, biosimilar) at ESMO 2020

Inovio Reports FDA’s Partial Clinical Hold on P-II/III Trial of INO-4800 Against COVID-19

Novavax Initiates P-III Study of its COVID-19 Vaccine in the UK

CSL Behring’s Haegarda (C1 Esterase Inhibitor) Receives the US FDA’s Approval for Pediatric Patients with Hereditary Angioedema

Pfizer’s Xeljanz (tofacitinib) Receives the US FDA’s Approval for Active Polyarticular Course Juvenile Idiopathic Arthritis

Inovio Reports FDA’s Partial Clinical Hold on P-II/III Trial of INO-4800 Against COVID-19

Sarepta Reports Two-Year Follow Up Results of SRP-9001 for Duchenne Muscular Dystrophy

Tags : Post

Novartis Reports Results of Five-year P-III MEASURE 1 and FUTURE

Amgen Launches Amgevita (adalimumab, biosimilar) in EU to Treat Inflammatory

Latest Posts

COVID-19 – Where Does The Pharmaceutical Industry Go From Here?

Inovio Reports FDA’s Partial Clinical Hold on P-II/III Trial of INO-4800 Against COVID-19

Boston Scientific Launches ACURATE neo2 Aortic Valve System in Europe

CSL Behring’s Haegarda (C1 Esterase Inhibitor) Receives the US FDA’s Approval for Pediatric Patients with Hereditary Angioedema

Tags : Post

Latest Posts

Categories

Related Topics